Sue DeLisle

21
Jun 2017
Share This
0 Comments

Growing Canada’s Talent Pool

Posted by

As Canada looks to grow our innovation economy, which is driven by entrepreneurship and increased productivity, the federal government has introduced a fast track work permit plan for highly skilled foreign workers to address our knowledge gap.   …

As Canada looks to grow our innovation economy, which is driven by entrepreneurship and increased productivity, the federal government has introduced a fast track work permit plan for highly skilled foreign workers to address our knowledge gap.   The program called Global Talent Stream launched June 12th and expedites the process for qualified and highly skilled talent to receive work permits in Canada within two weeks of applying.

“Being able to quickly attract the best and brightest minds to Canada — above and beyond the ones that already live here — is one way the federal government has listened to the needs of CEOs who are choosing to grow their companies in Canada”, notes Dr. Allen Eaves, President and CEO, STEMCELL Technologies Inc. in an opinion piece published in the Vancouver Sun .

Dr. Eaves knows first-hand what it takes to attract good people.  Starting with 8 employees in 1993, STEMCELL Technologies has grown to over 1,000 current employees and has plans to expand to over 4,000 in the next 10 years.  Over one-third of the staff hold a Doctorate or Masters and the majority of employees have a Bachelor of Science or Engineering degree.

This is good news for the stem cell sector as well as the general economy because of a multiplier effect.  According to economist Enrico Moretti, each new high-tech job creates five additional jobs in the service economy.  As quoted in the MIT Sloan Management Review, Moretti points out that “for each new high-tech job in a city, five additional jobs are ultimately created outside of the high-tech sector in that city,”   He cites occupations such as lawyers, teachers, nurses, waiters, hairdressers and carpenters.  This is three times higher than in other sectors such as manufacturing.

Click to read more Close
10
May 2017
Share This
0 Comments

New award launched to celebrate and promote stem cell science

Posted by

Applications for the Sartorius & Science Prize for Regenerative Medicine & Cell Therapy are being accepted now.  The annual prize will be awarded to a researcher whose work has advanced the field of regenerative medicine and cell therapy.…

Applications for the Sartorius & Science Prize for Regenerative Medicine & Cell Therapy are being accepted now.  The annual prize will be awarded to a researcher whose work has advanced the field of regenerative medicine and cell therapy.

The winner will receive $25,000 USD and their application essay will be published in Science magazine.  The Grand Prize also includes a 5-year membership to The American Association for the Advancement of Science (AAAS) and an online subscription to Science.

Details about the prize and the application guide can be found here.

The prize is to raise the awareness for the field and is a collaborative effort between Sartorius, a leading pharmaceutical and laboratory equipment company, and AAAS.

Click to read more Close
05
May 2017
Share This
0 Comments

Dr. Molly Shoichet awarded prestigious Killam Prize

Posted by

Recognized for the contributions she has made throughout her career to advancing the field of stem cell research and regenerative medicine, University of Toronto’s Dr. 

Recognized for the contributions she has made throughout her career to advancing the field of stem cell research and regenerative medicine, University of Toronto’s Dr. Molly Shoichet has been awarded a 2017 Killam Prize along with $100,000 to advance her work.

“This award will accelerate our research and our efforts to improve the lives of people everywhere who are living with the effects of cancer, stroke, blindness and other currently irreversible conditions” commented Dr. Shoichet in an article published by the University of Toronto.

Dr. Shoichet’s research focuses on using biomaterials to enhance the effectiveness of stem cells in the treatment of conditions such as blindness and stroke.  She developed a hydrogel platform to deliver stem cells to the brain and eyes to restore vision by 15 per cent.  For that, and her other contributions to the field of stem cell research, Dr. Shoichet received the 2016 Till & McCulloch Award.

Beyond her research endeavors, Dr. Shoichet is a strong advocate for women in science and technology careers and was the L’Oreal-UNESCO Women in Science Laureate, North America for 2015.  She also advocates for Canadian innovation and co-authored a piece published last year in iPolitics to promote Canada’s global leadership in the field of stem cell research and regenerative medicine.

Click to read more Close
04
Apr 2017
Share This
0 Comments

Congratulations to Dr. Alan Bernstein – Awarded 2017 Henry G. Friesen International Prize

Posted by

Dr. Alan Bernstein, Chair of the Canadian Stem Cell Foundation, has been awarded the 2017 Henry G. Friesen International Prize in Health Research for his significant contributions to health and innovation.   …

Dr. Alan Bernstein, Chair of the Canadian Stem Cell Foundation, has been awarded the 2017 Henry G. Friesen International Prize in Health Research for his significant contributions to health and innovation.   The prize, established in 2005, recognizes “exceptional innovation by a visionary health leader”.

As the press release notes, there are many examples of Dr. Bernstein’s impact on health research and his ability to build strong collaborations.

  • As the inaugural President of the Canadian Institutes of Health Research, he brought together biomedical, clinical and social scientists and set the standard for transdisciplinary research in Canada.
  • Serving as the Executive Director of the Global HIV Vaccine Enterprise in New York, Dr. Bernstein built an international alliance of researchers and funders to accelerate the development of HIV vaccines.
  • As the President & CEO of the Canadian Institute for Advanced Research, he promotes collaboration on a global scale by forging partnerships between international researchers to work on health, social and technological challenges.

Dr. Bernstein’s own stem cell and cancer research is rooted in strong partnerships as we wrote about here when he was inducted into the Canadian Medical Hall of Fame.   A fellow of both the Royal Society of Canada and the Canadian Academy of Health Science, he is an Officer of the Order of Canada.

As the Chair of the Canadian Stem Cell Foundation, Dr. Bernstein was instrumental in the collaborative effort that brought together 150 scientists, doctors, leaders from health charities, industry experts and philanthropists to craft the Canadian Stem Cell Strategy with a unified vision to deliver 10 new stem cell therapies to the clinic within 10 years.

“Helen Keller is attributed with the quote ‘Alone we can do so little; together we can do so much’ and Alan’s career characterizes the sentiment,”  noted James Price, President & CEO of the Canadian Stem Cell Foundation,  “We congratulate Dr. Bernstein on this award and thank him for his exemplary leadership”.

Click to read more Close
16
Mar 2017
Share This
1 Comment

Unproven stem cell treatment leaves three women blind

Posted by

Three women who believed they were participating in a clinical trial either lost all or most of their vision after being injected with stem cells derived from their own fat in a Florida clinic. …

Three women who believed they were participating in a clinical trial either lost all or most of their vision after being injected with stem cells derived from their own fat in a Florida clinic.  The case points to the dangers of unproven treatments offered by private clinics.

Within days of treatment the women, who all suffered from macular degeneration, began to experience severe side effects including bleeding in the eye, detached retinas and vision loss as reported in a study released week in The New England Journal of Medicine.   Expert ophthalmologists tried to reverse the damage but were unable.

“There’s a lot of hope for stem cells, and these types of clinics appeal to patients desperate for care who hope that stem cells are going to be the answer, but in this case these women participated in a clinical enterprise that was off-the-charts dangerous”  said Dr. Thomas Alibini, a lead author of the study, in a press release.

This isn’t the first time there have been adverse reactions to unproven treatments offered at clinics, many using stem cells drawn from the patient’s own fat, and we’ve written about it several times on this blog warning patients to be cautious of claims that appear too good to be true.

So how can patients protect themselves?  The California Institute of Regenerative Medicine offers this advice:

  • There is almost no evidence that the fat/blood stem cell combination the clinic used could help repair the photoreceptor cells in the eye that are attacked in macular degeneration.
  • The clinic charged the women $5,000 for the procedure. Usually in Food and Drug Administration (FDA)-approved trials the clinical trial sponsor will cover the cost of the therapy being tested.
  • Both eyes were injected at the same time.  Most clinical trials would only treat one eye at a time and allow up to 30 days between patients to ensure the approach was safe.
  • Even though the treatment was listed on the clinicaltrials.gov website, there is no evidence that this was part of a clinical trial, and certainly not one approved by the FDA.

Most importantly, patients should check with their doctor before considering any medical treatment or participating in any clinical trial.  You can also find great information for patients considering stem cell treatments here that has been produced by the International Society for Stem Cell Research (ISSCR).

Click to read more Close
15
Dec 2016
Share This
0 Comments

New test helps tailor treatments for high-risk leukemia patients

Posted by

Researchers at Princess Margaret Cancer Centre in Toronto have developed a test to predict responses to standard treatments in patients with acute myeloid leukemia (AML) — one of the most deadly and common types of adult leukemia.…

Researchers at Princess Margaret Cancer Centre in Toronto have developed a test to predict responses to standard treatments in patients with acute myeloid leukemia (AML) — one of the most deadly and common types of adult leukemia.

The test is designed to be administered in tandem with diagnosis so that once the marker is identified, an individual treatment plan can be prepared.

“Clinicians will now have a tool that they can use upfront to tailor treatment to risk in AML,” says Dr. Jean Wang, Affiliate Scientist at the Princess Margaret and Co-Principle Investigator of the study in a press release from the University Health Network.

The marker identifies a 17-gene signature derived from leukemia stem cells that are resistant to standard chemotherapy and cause relapse for patients. Based on a rigorous statistical approach, a “stemness score” measures a patient’s probability for chemo resistant cells. With this knowledge, clinicians will be able to enroll high-risk patients in clinical trials to test alternative therapies to chemotherapy alone.

The test not only provides a fast turnaround time for patients as they decide the best course of care, it also represents the first time a stem cell-based biomarker has been developed in this way for human cancer.

Click to read more Close
14
Nov 2016
Share This
0 Comments

McMaster’s research centre marks decade with new site/logo

Posted by

After a decade of innovation, McMaster’s Stem Cell and Cancer Research Institute (SCC-RI) has launched a new website to draw attention to research advances and share links to resources for patients, care givers and future scientists. …

After a decade of innovation, McMaster’s Stem Cell and Cancer Research Institute (SCC-RI) has launched a new website to draw attention to research advances and share links to resources for patients, care givers and future scientists.  The SCC-RI’s new logo, a stylized hand, represents the numerous people involved in translating research into new therapeutic options for patients.

The SCC-RI was established in 2006 — the same year Dr. Shinya Yamanaka established his game-changing protocol to turn adult skin stem cells back to an embryonic stem cell-like state of pluripotency — to drive new therapies to the clinic. Since the beginning, SCC-RI has focused its research on improving bone marrow and cord blood transplants, finding cell-based solutions to cancer and identifying and targeting the cells responsible for neural disorders such as autism.

“Our commitment to working with human cells and our established drug discovery capabilities make this the best place for moving forward to patient-specific drug discovery,” said Dr. Karun Singh, Principal Investigator at SCC-RI in a recent blog post.

Dr. Singh recently led a team that discovered a gene mutation that causes autism spectrum disorders (ASD).  Having identified the genetic glitch, researchers can now focus their efforts on finding a way to improve the brain connections that are causing symptoms of ASD.

The SCC-RI team has developed a robotic system to test a library of currently available drugs on a variety of diseased cells before starting human trials. In a landmark study, Dr. Mick Bhatia, SCC-RI Director and Senior Scientist, found the antipsychotic drug, thioridazine, kills cancer stem cells responsible for initiating leukemia without harming normal stem cells. A  Phase I clinical trial is now underway.

 

Click to read more Close
08
Nov 2016
Share This
0 Comments

Allen Eaves wins Entrepreneur of the Year Pacific Region

Posted by

Dr. Allen Eaves, President and CEO of STEMCELL Technologies Inc., has been awarded Entrepreneur of the Year Pacific Winner by Ernst and Young Canada.…

Dr. Allen Eaves, President and CEO of STEMCELL Technologies Inc., has been awarded Entrepreneur of the Year Pacific Winner by Ernst and Young Canada.

The theme for the 2016 awards is recognizing accelerators — those entrepreneurs who “accelerate all of us by bringing us new products and services and by driving our economy” explains Lui Pettrollini, Entrepreneur of the Year Pacific Program Director, in an article carried in the Globe & Mail’s Report On Business Magazine.

Dr. Eaves founded STEMCELL in 1993 to support his own research as the head of the BC Cancer Agency’s Terry Fox Laboratory in Vancouver. Unable to source what he needed to support his research, Dr. Eaves began making media for growing blood-forming stem cells. Today, STEMCELL Technologies offers more than 2,000 cell biology tools to researchers in over 80 countries. It is Canada’s largest biotech company with 850 employees and $150 million in annual sales.

“I run my company like a graduate training program,” Dr. Eaves said in the ROB Magazine piece. “Scientists have a lot of freedom in deciding what they can work on and that inspires them to be creative and think clever thoughts.”

Dr. Eaves has also developed a group of companies including STEMSOFT Software Inc., that makes software for managing data in bone marrow centres, cord blood banks, cellular therapy companies as well as tumour and tissue repositories. He also founded Malachite Management Inc., which provides association management, conference management, fundraising and strategic planning to medical and scientific organizations.

Dr. Eaves is a major supporter of the Canadian Stem Cell Foundation as both a member of the Board of Directors and a founding Till & McCulloch Leadership Circle member.

Dr. Eaves’ accomplishments will be celebrated along with other regional winners on November 22nd at the EY National Awards Gala in Toronto.

Click to read more Close
21
Oct 2016
Share This
0 Comments

Trainees meet with top researchers at the T&M conference

Posted by

Billed as “Canada’s premier stem cell research event” the Till & McCulloch Meetings provide an excellent opportunity for young scientists to discuss their work with sector leaders and talk about how they can play a role in advancing regenerative medicine.…

Billed as “Canada’s premier stem cell research event” the Till & McCulloch Meetings provide an excellent opportunity for young scientists to discuss their work with sector leaders and talk about how they can play a role in advancing regenerative medicine.

Named after Drs. James Till and Ernest McCulloch, who discovered stem cells in 1961, the annual conference attracts hundreds of participants from across Canada and all over the world. The meetings, which begin Monday and run through Wednesday in Whistler, BC, foster new collaborations and nurture Canadian leadership and innovation.

Since the conference was first organized in 2001, much effort has been made to support young scientists via networking sessions, workshops and presentations. Top trainees are acknowledged with awards for their poster submissions, presentations and research efforts

Recognizing the importance of the trainee experience in Canada, a special session will be held to develop programs for young investigators. Participants will be asked to recommend the types of workshops and skills development best suited to support trainees and will participate in organizing them. Previous sessions have included workshops in career development, grant review and journal writing and ethics.

For more information on the Till & McCulloch Meetings 2016 click here. 

Tagged in:
Click to read more Close
20
Oct 2016
Share This
0 Comments

Celebrating the 55th anniversary of one of Canada’s greatest medical discoveries

Posted by

Fifty-five years ago, Drs. James Till and Ernest McCulloch identified stem cells and provided the theoretical underpinning for bone marrow transplant procedures that have saved the lives of countless leukemia patients.…

Fifty-five years ago, Drs. James Till and Ernest McCulloch identified stem cells and provided the theoretical underpinning for bone marrow transplant procedures that have saved the lives of countless leukemia patients. It also opened up the field of stem cell science.

To commemorate the breakthrough, which ranks as one of Canada’s greatest medical discoveries, Science World at TELUS World of Science in Vancouver will unveil a bronze portrait of Drs. Till and McCulloch on Sunday.

“It’s impossible to overstate the impact of Dr. Till and Dr. McCulloch’s discovery and their long-time collaboration,” says, Dr. Allen Eaves, President & CEO of STEMCELL Technologies Inc. that commissioned the work of art. “Their work changed the course of cancer research and paved the way for what we now call regenerative medicine.”

Both Dr. Eaves, who co-founded the Terry Fox Laboratory with the BC Cancer Agency, and his wife, prominent cancer researcher Dr. Connie Eaves, were greatly influenced by Drs. Till and McCulloch during their time at the Ontario Cancer Institute in Toronto. Connie was a post-doctoral fellow who worked closely with them and Allen used their methodology in his own cancer research, which led him to set up the first bone marrow transplantation program in Western Canada.

The sculpture was created by renowned artist Ruth Abernethy, whose public portraits in bronze have celebrated the achievements of several prominent Canadians. She is probably best known for her depiction of Glenn Gould sitting on a bench at CBC in Toronto and Oscar Peterson tinkling a piano outside the National Arts Centre in Ottawa. She will attend the unveiling Sunday to talk about her work and sign copies of Life and Bronze: a Sculptor’s Journal.

The accomplishments of Drs. Till and McCulloch are also celebrated in the book Dreams & Due Diligence: Till and McCulloch’s Stem Cell Discovery and Legacy. Author Joe Sornberger will be at the unveiling Sunday to sign copies of his book.  The book is available for purchase on our website by clicking on this link.

The public is welcome to attend the unveiling at Science World at 1455 Quebec Street on Sunday at 1 p.m. Next spring, a sister bronze portrait will be installed at the MaRS Building in downtown Toronto.

Click to read more Close
Back to Top